Zacks Investment Management Terns Pharmaceuticals, Inc. Transaction History
Zacks Investment Management
- $12.1 Billion
- Q3 2025
A detailed history of Zacks Investment Management transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 36,100 shares of TERN stock, worth $811,528. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,100
Previous 14,864
142.87%
Holding current value
$811,528
Previous $55,000
398.18%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TERN
# of Institutions
152Shares Held
90.3MCall Options Held
574KPut Options Held
41.6K-
Soleus Capital Management, L.P. Greenwich, CT8.13MShares$183 Million3.76% of portfolio
-
Morgan Stanley New York, NY7.59MShares$171 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$170 Million1.96% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.5MShares$168 Million1.8% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$155 Million8.33% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $846M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...